Bioatla (BCAB) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Bruce Mackle - Managing DirectorJay Short - Co-Founder, CEO & ChairmanRichard Waldron - Chief Financial OfficerEric Sievers - Chief Medical OfficerSheri Lydick - Chief Commercial OfficerTony Butler - Senior Managing Director Conference Call Participants Jeet Mukherjee - AnalystNone - AnalystArthur He - Analyst Operator is now my pleasure to turn the conference over to Mr. Bruce Mackle of LifeSci Advisors. Please go ahead, s ...

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS SAN DIEGO, March 27, 2025 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided highlights on its clinical programs. "We are encouraged by the differenti ...

Core Insights - BioAtla, Inc. reported encouraging clinical outcomes from its Conditionally Active Biologic (CAB) platform, particularly in its Phase 1 dose-escalation study for dual conditionally-binding EpCAM and CD3, with multiple patients showing tumor reduction and tolerating therapy without progression [2][4][5] - The company has restructured its organization to reduce costs and extend its financial runway, focusing on prioritizing patient recruitment for programs expected to yield transformative results [2][10][13] Financial Performance - For Q4 2024, research and development (R&D) expenses were $11.6 million, down from $22.7 million in Q4 2023, attributed to lower clinical development expenses due to program prioritization [10] - General and administrative (G&A) expenses decreased to $4.6 million in Q4 2024 from $5.9 million in Q4 2023, primarily due to lower stock-based compensation and personnel costs [11] - The net loss for Q4 2024 was $14.9 million, a reduction from a net loss of $26.9 million in the same quarter of 2023 [11] - Cash and cash equivalents at year-end 2024 stood at $49 million, down from $111.5 million at the end of 2023, with expectations that cost reductions will extend the runway beyond key clinical readouts in 1H 2026 [13][26] Clinical Program Updates - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with data readout expected in mid-2025, and dose expansion data anticipated in 1H 2026 [4][5] - Mecbotamab vedotin (CAB-AXL-ADC) demonstrated a 66% overall survival rate at one year and 58% at two years among patients with mKRAS NSCLC, exceeding standard care benchmarks [4][9] - Ozuriftamab vedotin (CAB-ROR2-ADC) showed promising anti-tumor activity in treatment-refractory metastatic HPV-positive squamous cell carcinoma of the head and neck, with a 45% overall response rate [4][19] Corporate Strategy and Future Outlook - The company is advancing multiple discussions with potential collaborators for its Phase 2 assets while initiating new partnerships [2][6] - BioAtla is focusing on its two internal priority programs and has initiated workforce reductions of over 30% to align resources effectively [10][12] - The management plans to host a conference call to discuss these developments and financial results, indicating a commitment to transparency with stakeholders [14]

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 an ...

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call and Webcast I ...

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock offered was s ...

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antitumor activity observed across 9 different mKRAS variants Strong association of AXL expression by mKRAS NSCLC confirmed SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSW ...

Core Insights - BioAtla, Inc. presented promising data on Mecbotamab Vedotin (Mec-V) for treatment-refractory non-small cell lung cancer (NSCLC) with mutated KRAS (mKRAS), showing a one-year overall survival (OS) of 58% compared to 23% for wild-type KRAS (wtKRAS) patients [1][3][4] Group 1: Clinical Trial Results - The Phase 2 trial of Mec-V included 78 patients, with 30.7% having mKRAS NSCLC [4] - Among patients with mKRAS NSCLC, the median OS was not yet reached, while the median OS for wtKRAS was 8.7 months [4] - The overall response rate (ORR) for mKRAS NSCLC patients was 28.6%, with notable antitumor activity across 9 different mKRAS variants [4] Group 2: Mechanism and Targeting - Mec-V is a conditionally active antibody-drug conjugate targeting AXL, which is highly expressed in mKRAS NSCLC [6][4] - A strong correlation was confirmed between mKRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring KRAS mutations showing high AXL expression [3][4] Group 3: Future Plans - BioAtla plans to initiate a randomized trial of Mec-V in 2025 for patients with treatment-refractory mKRAS NSCLC based on the encouraging findings [3][4] - The company has received Orphan Drug Designation from the FDA for Mec-V in treating soft tissue sarcoma, indicating its potential across multiple solid tumor indications [6]

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...